


TRANSLATION FROM HEREW ORIGINAL

BIO VIEW LTD.
2021 ANNUAL REPORT

BIO VIEW LTD.
2021 ANNUAL REPORT

TABLE OF CONTENTS

	Page
CONSOLIDATED FINANCIAL STATEMENTS - IN NEW ISRAELI SHEKELS (NIS):	
Statements of financial position	F-3
Statements of income or loss	F-4
Statements of comprehensive income (loss)	F-5
Statements of cash flows	F-6



BIO VIEW LTD.
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

A s s e t s	Note	December 31	
		2021	2020
		NIS in thousands	
CURRENT ASSETS:			
Cash and cash equivalents	5	19,223	17,239
Accounts receivable:	6		
Trade		4,418	3,223
Other		489	568
Inventory	7	4,600	4,377
		<u>28,730</u>	<u>25,407</u>
NON-CURRENT ASSETS :			
Restricted deposit	13a	220	125
Other long-term receivables	3a	699	699
Right of use asset	13	4,247	1,503
Deferred income tax	8	5,013	5,465
Property and equipment - net		1,108	690
		<u>11,287</u>	<u>8,482</u>
T O T A L A S S E T S		<u>40,017</u>	<u>33,889</u>
Liabilities and equity			
CURRENT LIABILITIES:			
Accounts payable:	9		
Trade		1,280	1,177
Other		2,645	2,401
Prepaid income	11	2,961	2,837
Current maturities of lease liabilities	13	1,081	1,067
Provision for warranty	10	401	355
		<u>8,368</u>	<u>7,837</u>
NON-CURRENT LIABILITIES:			
Retirement benefit obligation - net	14	429	441
Prepaid income	11	533	147
Lease liabilities	13	3,527	395
		<u>4,489</u>	<u>983</u>
COMMITMENTS AND CONTINGENT LIABILITIES	12		
T O T A L L I A B I L I T I E S		<u>12,857</u>	<u>8,820</u>
EQUITY ATTRIBUTED TO COMPANY'S OWNERS:			
Ordinary shares	15	141	141
Share premium		53,044	53,044
Capital surplus in respect of options		744	661
Other comprehensive loss reserves		(1,318)	(1,142)
Treasury shares		(671)	(671)
Accumulated deficit		(24,780)	(26,964)
TOTAL EQUITY		<u>27,160</u>	<u>25,069</u>
TOTAL LIABILITIES AND EQUITY		<u>40,017</u>	<u>33,889</u>

Emmanuel Gil
Chairman of the
Board of Directors

Dr. Alan Schwebel
CEO

Yulia Kapon
Director of Finance

Date of approval of financial statements by the Board of Directors: March 19, 2021.

The accompanying notes are an integral part of these financial statements.

BIO VIEW LTD.
CONSOLIDATED STATEMENTS OF INCOME OR LOSS

	Note	Year ended December 31		
		2021	2020	2019
NIS in thousands				
REVENUE	16a	30,513	25,960	35,790
COST OF SALES	16b	12,927	10,176	15,523
GROSS PROFIT		17,586	15,784	20,267
RESEARCH AND DEVELOPMENT EXPENSES	16c	5,325	5,354	5,708
SELLING AND MARKETING EXPENSES	16d	4,349	4,035	4,837
GENERAL AND ADMINISTRATIVE EXPENSES	16e	5,355	4,730	5,381
OTHER EXPENSES (INCOME) (MAINLY FOREIGN EXCHANGE RATE DIFFERENCES), NET	16f	(393)	464	946
OPERATING INCOME (LOSS)		2,950	1,201	3,395
FINANCE EXPENSES (INCOME) – NET	16g	267	60	27
INCOME (LOSS) BEFORE TAXES ON INCOME		2,683	1,141	3,368
INCOME TAX (TAX BENEFITS)	8	499	257	843
NET INCOME (LOSS) FOR THE YEAR		2,184	884	2,525
NIS				
EARNINGS (LOSS) PER SHARE:	17			
Basic income (loss) per share		0.16	0.06	0.18
Diluted income (loss) per share		0.16	0.06	0.18

The accompanying notes are an integral part of these financial statements.

TRANSLATION FROM HEREW ORIGINAL

BIO VIEW LTD.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

	Year ended December 31		
	2021	2020	2019
	NIS in thousands		
NET INCOME (LOSS) FOR THE YEAR	<u>2,184</u>	<u>884</u>	<u>2,525</u>
OTHER COMPREHENSIVE INCOME (LOSS):			
Items that will not be reclassified to profit or loss -			
remeasurement of post-employment benefit obligations	12	76	(166)
Items that may be subsequently reclassified to profit or loss -			
foreign exchange differences arising from translation of the net investment in foreign operation	(188)	(329)	(345)
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)	<u>(176)</u>	<u>(253)</u>	<u>(511)</u>
COMPREHENSIVE INCOME (LOSS) FOR THE YEAR	<u>2,008</u>	<u>631</u>	<u>2,014</u>

The accompanying notes are an integral part of these financial statements.

BIO VIEW LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

(Continued) - 1

BIO VIEW LTD.

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Year ended December 31		
	2021	2020	2019
	NIS in thousands		
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net cash generated by (used in operations) (see appendix A)	3,479	933	2,845
Income tax paid – net	-	(85)	(275)
Interest paid on lease	(232)	(46)	(74)
Net cash provided by (used in) operations	<u>3,247</u>	<u>802</u>	<u>2,496</u>
CASH FLOWS FROM INVESTING ACTIVITIES:			
Acquisition of property and equipment	(659)	(304)	(208)
Sale of property and equipment	14	-	-
Increase in Restricted deposit	(95)	-	-
Deposits – net	-	(9)	(18)
Net cash used in investing activities	<u>(740)</u>	<u>(313)</u>	<u>(226)</u>
CASH FLOWS FROM FINANCING ACTIVITIES:			
Maturity of lease liability	(861)	(1,027)	(1,047)
Cost of Treasury Shares	-	(671)	-
Short Term Loan	593	-	-
Exercise of warrants into shares by employees	-	98	66
Net cash provided by (used in financing activities)	<u>(268)</u>	<u>(1,600)</u>	<u>(981)</u>
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	2,239	(1,111)	1,289
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	17,239	18,743	18,007
INCOME (LOSS) FROM FOREIGN EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS	(255)	(393)	(553)
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR	<u>19,223</u>	<u>17,239</u>	<u>18,743</u>

The accompanying notes are an integral part of these financial statements.

BIO VIEW LTD.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)

(Concluded) - 2

BIO VIEW LTD.

CONSOLIDATED STATEMENTS OF CASH FLOWS

	<u>2021</u>	<u>2020</u>	<u>2019</u>
	<u>NIS in thousands</u>		
APPENDIXES TO STATEMENT OF CASH FLOWS:			
(a) Net cash provided by (used in operating activities):			
Income (loss) before taxes on income	2,683	1,141	3,368
Adjustments in respect of – income and expense not involving cash flows:			
Depreciation and amortization	1,476	1,228	1,402
Amounts charged in respect of options to employees	83	61	121
Interest paid on lease	232	46	63
Short term loan turning in to a grant	(593)	-	-
Loss from sale of equipment	12	-	-
Loss from foreign exchange rate differences on cash and cash equivalents	(100)	(306)	(316)
	<u>3,793</u>	<u>2,170</u>	<u>4,638</u>
Changes in operating asset and liability items:			
Decrease (increase) in accounts receivable:			
Trade	(1,243)	1,005	(1,318)
Other	29	(9)	73
Increase in inventory	(264)	(655)	(105)
Increase (decrease) in accounts payable and accruals:			
Trade	109	(146)	(206)
Other (including provision for warranty)	437	(312)	669
Decrease in provision for royalties to Chief Scientist	-	-	(422)
Increase (decrease) in prepaid income (including long-term prepaid income)	618	(1,120)	(484)
	<u>(314)</u>	<u>(1,237)</u>	<u>(1,793)</u>
Net cash provided by (used in operating activities)	<u>3,479</u>	<u>933</u>	<u>2,845</u>
(b) Information regarding interest received in cash	<u>21</u>	<u>44</u>	<u>86</u>
(c) Information about investing and financing activities not involving cash flows:			
Right of use of assets	<u>4,006</u>	<u>75</u>	<u>722</u>

The accompanying notes are an integral part of these financial statements